---
schema_version: "secwatch.filing_event.v1"
accession: "0001847367-25-000039"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:59:41.662715+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alumis Q2 net income $59.3M (incl. $187.9M merger gain); Phase 3 psoriasis & Phase 2b SLE enrollment complete

## Summary
- Cash, cash equivalents and marketable securities of $486.3M as of June 30, 2025; expects to fund operations into 2027.
- Phase 3 ONWARD trials (psoriasis) fully enrolled; topline data expected early Q1 2026.
- Phase 2b LUMUS trial (SLE) fully enrolled with 408 patients; topline data expected Q3 2026.
- Completed merger with ACELYRIN, adding $382.6M cash; total merger-related expenses of $26.8M in Q2.
- R&D expenses $108.8M (up from $48.6M); G&A $34.5M (up from $7.6M) driven by merger costs and clinical acceleration.

## SEC filing metadata
- accession: 0001847367-25-000039
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/0001847367-25-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847367-25-000039
- JSON: https://secwatch.observer/filing/0001847367-25-000039.json
- Plain text: https://secwatch.observer/filing/0001847367-25-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.